[1] Evaluation of the SARS-CoV-2 RNA detection reagent LAMPdirect Genelyzer KIT using nasopharyngeal swab and saliva samples.
Takeuchi J S, Fukano K, Kito Y, Yamamoto K, and Kimura M.
Diagnostic Microbiology and Infectious Disease, 2024. 109(3): p. 116297.
https://doi.org/10.1016/j.diagmicrobio.2024.116297

[2] Relapse of COVID-19 and Viral Evolution in a Patient With Good Syndrome: A Case Report.
Iwasaki M, Hashimoto M, Takeuchi J S, Kusaba Y, Kimura M, Terada-Hirashima J, Sugiura W, and Hojo M.
Cureus, 2024. 16(1): p. e52592.
https://pubmed.ncbi.nlm.nih.gov/38371040/

[1] Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Nemoto T, Takeuchi J S, Li Y, Konishi M, Tsuchiya K, Gatanaga H, Oka S, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W and Ohmagari N.
J Infect Dis 228(12): 1652-1661.
https://doi.org/10.1093/infdis/jiad317

[2] SARS-CoV-2 HaploGraph: visualization of SARS-CoV-2 haplotype spread in Japan.
Nakagawa S, Katayama T, Jin L, Wu J, Kryukov K, Oyachi R, Takeuchi J S, Fujisawa T, Asano S, Komatsu M, Onami J I, Abe T and Arita M.
Genes Genet Syst 98(5): 221-237.
https://doi.org/10.1266/ggs.23-00085

[3] Examination of the utility of the COVID-19 detection kit, TRC Ready((R)) SARS-CoV-2 i for nasopharyngeal swabs.
Ishii S, Kimura M, Miyoshi-Akiyama T, Moriya A, Kurokawa M, Isaka E, Terada-Hirashima J, Takasaki J, Izumi S, Hojo M, and Sugiyama H.
Drug Discov Ther, 2023. 17(2): p. 134-138.
https://doi.org/10.5582/ddt.2022.01106

[4] Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
Yamamoto S, Matsuda K, Maeda K, Oshiro Y, Inamura N, Mizoue T, Konishi M, Takeuchi J S, Horii K, Ozeki M, Sugiyama H, Mitsuya H, Sugiura W and Ohmagari N.
BMC Infect Dis 23(1): 282.
https://doi.org/10.1186/s12879-023-08272-2

[5] Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan.
Li Y, Yamamoto S, Oshiro Y, Inamura N, Nemoto T, Horii K, Takeuchi J S, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Sugiura W, and Ohmagari N.
J Hosp Infect, 2023. 134: p. 97-107.
https://doi.org/10.1016/j.jhin.2023.01.018.

[1] Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-lambda3, CCL17, and calprotectin considering the timing of clinical need for prediction.
Yamamoto K, Ohsiro Y, Suzuki T, Suzuki M, Miura S, Nagashima M, Iwamoto N, Takeuchi J S, Kimura M, Sugiura W, Nebuya S, Kurokawa M, and Ohmagari N.
PLoS One, 2023. 18(3): p. e0279897.
https://doi.org/10.1371/journal.pone.0279897

[2] Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Takeuchi J S, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, and Ohmagari N.
Int J Infect Dis, 2023. 128: p. 347-354.
https://doi.org/10.1016/j.ijid.2023.01.023

[3] Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Terada-Hirashima J, Takamatsu Y, Shimizu Y, Uemura Y, Takeuchi J S, Tomita N, Matsuda K, Maeda K, Yamamoto S, Fukunaga A, Ohmagari N, Mikami A, Sonoda K, Ujiie M, Mitsuya H and Sugiura W.
Hum Vaccin Immunother 19(1): 2193074.
https://doi.org/10.1080/21645515.2023.2193074

[4] Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
Okumura N, Saito S, Takamatsu Y, Takeuchi J S, Asai Y, Sanada M, Iwamoto N, Maeda K, Mitsuya H, and Ohmagari N.
J Infect Chemother, 2022. 28(12): p. 1704-1706.
https://doi.org/10.1016/j.jiac.2022.08.026

[5] SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study.
Takeuchi J S, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Kamikawa A, Kito Y, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, and Sugiura W.
Sci Rep, 2022. 12(1): p. 15447.
https://doi.org/10.1038/s41598-022-19581-y

[6] Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
Okumura N, Tsuzuki S, Saito S, Hattori S I, Takeuchi J S, Saito T, Ujiie M, Hojo M, Iwamoto N, Sugiura W, Mitsuya H, and Ohmagari N.
J Infect Chemother, 2022. 28(9): p. 1340-1343.
https://doi.org/10.1016/j.jiac.2022.04.018

[7] Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato Y, Yamamoto K, Nakaya Y, Morioka S, Takeuchi J S, Takamatsu Y, Maeda K, Kimura M, Sugiura W, Mitsuya H, Yano M, and Ohmagari N.
J Infect Chemother, 2022. 28(7): p. 991-994.
https://doi.org/10.1016/j.jiac.2022.03.002

[8] Investigation of the use of PCR testing prior to ship boarding to prevent the spread of SARS-CoV-2 from urban areas to less-populated remote islands.
Terada-Hirashima J, Sugiura W, Shimizu Y, Tanaka Y, Uemura Y, Ishikane M, Kazuyama Y, Ikeda M, Wakabayashi K, Ohmagari N, and Kimura M.
Glob Health Med, 2022. 4(3): p. 174-179.
https://doi.org/10.35772/ghm.2022.01008

[9] Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA).
Terayama Y, Tomita N, Terada-Hirashima J, Uemura Y, Shimizu Y, Takeuchi J S, Takamatsu Y, Maeda K, Mikami A, Ujiie M, and Sugiura W.
Life (Basel), 2022. 12(7).
https://doi.org/10.3390/life12070966

[10] Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 panel, a rapid multiplex PCR method for the diagnosis of COVID-19.
Ishikane M, Unoki-Kubota H, Moriya A, Kutsuna S, Ando H, Kaburagi Y, Suzuki T, Iwamoto N, Kimura M, and Ohmagari N.
J Infect Chemother, 2022. 28(6): p. 729-734.
https://doi.org/10.1016/j.jiac.2022.02.004

[11] Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, and Ishizaka Y.
Antiviral Res, 2022. 201: p. 105297.
https://doi.org/10.1016/j.antiviral.2022.105297

[12] An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
Khor S S, Omae Y, Takeuchi J S, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, Sugiura W, and Tokunaga K.
Vaccines (Basel), 2022. 10(4).
https://doi.org/10.3390/vaccines10040563

[1] Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
Yamamoto S, Fukunaga A, Tanaka A, Takeuchi J S, Inoue Y, Kimura M, Maeda K, Ueda G, Mizoue T, Ujiie M, Sugiura W, and Ohmagari N.
Vaccine, 2022. 40(13): p. 1924-1927.
https://doi.org/10.1016/j.vaccine.2022.02.052

[2] Time-course evaluation of the quantitative antigen test for severe acute respiratory syndrome coronavirus 2: The potential contribution to alleviating isolation of COVID-19 patients.
Nomoto H, Yamamoto K, Yamada G, Suzuki M, Kinoshita N, Takasaki J, Moriya A, Maeda K, Kimura M, and Ohmagari N.
J Infect Chemother, 2021. 27(11): p. 1669-1673.
https://doi.org/10.1016/j.jiac.2021.08.015

[3] Correlation between asymptomatic cases and the incidence of COVID-19 in Japan.
Kimura M, Uemura Y, Omagari N, Ikeda M, Sugiura W.
Epidemiology and Public Health Research.
https://geneft.com/article/correlation-between-asymptomatic-cases-and-the-incidence-of-covid-19-in-japan

[4] Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, Takeuchi J S, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, and Ohmagari N.
Clin Infect Dis, 2022. 75(1): p. e683-e691.
https://doi.org/10.1093/cid/ciab1048

[5] Corrigendum to "Utility of the antigen test for coronavirus disease 2019: factors influencing the prediction of the possibility of disease transmission" [Int J Infect Dis 104 (2021) 65-72].
Yamamoto K, Suzuki M, Yamada G, Sudo T, Nomoto H, Kinoshita N, Nakamura K, Tsujimoto Y, Kusaba Y, Morita C, Moriya A, Maeda K, Yagi S, Kimura M, and Ohmagari N.
Int J Infect Dis, 2021. 109: p. 323.
https://doi.org/10.1016/j.ijid.2021.06.009

[6] Diagnostic accuracy of nasopharyngeal swab, nasal swab and saliva swab samples for the detection of SARS-CoV-2 using RT-PCR.
Tsujimoto Y, Terada J, Kimura M, Moriya A, Motohashi A, Izumi S, Kawajiri K, Hakkaku K, Morishita M, Saito S, Takumida H, Watanabe H, Tsukada A, Morita C, Yamaguchi Y, Katsuno T, Kusaba Y, Sakamoto K, Hashimoto M, Suzuki M, Takasaki J, Hojo M, Miyoshi-Akiyama T, and Sugiyama H.
Infect Dis (Lond), 2021. 53(8): p. 581-589.
https://doi.org/10.1080/23744235.2021.1903550

[7] Effective screening strategies for detection of asymptomatic COVID-19 travelers at airport quarantine stations: Exploratory findings in Japan.
Norizuki M, Hachiya M, Motohashi A, Moriya A, Mezaki K, Kimura M, Sugiura W, Akashi H, and Umeda T.
Glob Health Med, 2021. 3(2): p. 107-111.
https://doi.org/10.35772/ghm.2020.01109

[1] Utility of the antigen test for coronavirus disease 2019: Factors influencing the prediction of the possibility of disease transmission.
Yamamoto K, Suzuki M, Yamada G, Sudo T, Nomoto H, Kinoshita N, Nakamura K, Tsujimoto Y, Kusaba Y, Morita C, Moriya A, Maeda K, Yagi S, Kimura M, and Ohmagari N.
Int J Infect Dis, 2021. 104: p. 65-72.
https://doi.org/10.1016/j.ijid.2020.12.079